Media & Investors

Press Release

« Back

Calithera to Present at Cowen & Company 38th Annual Health Care Conference


SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage biotechnology company focused on the development of novel cancer therapeutics, today announced that Susan M. Molineaux, Ph.D, the company’s Founder, President and Chief Executive Officer, will present at the Cowen & Company 38th Annual Health Care Conference at 10:40 a.m. ET on Tuesday, March 13, 2018 in Boston. The presentation will be webcast live and available for replay for up to 30 days at in the Investor Relations section.

About Calithera

Calithera is a clinical-stage biotechnology company focused on fighting cancer by discovering, developing, and commercializing novel small molecule drugs that target tumor and immune cell metabolism. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of CB-839, the overall advancement of CB-839 in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue development of CB-839 in combination with everolimus for the treatment of clear cell renal cell carcinoma. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission at These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

SOURCE: Calithera Biosciences, Incorporated


Jennifer McNealey


Primary Logo

Source: Calithera Biosciences, Inc.